BioToxTech Co

BioToxTech Co Net Margin

The Net Profit Margin of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 2.47 %. In the previous year, Net Profit Margin was -15.55 % — a change of -115.91% (higher).

Net Margin

2.47 %

YoY

-115.91%

Last updated:

Net Profit Margin of BioToxTech Co is 2025 2.47 % . Net Profit Margin of BioToxTech Co was 2024 -15.55 % . It decreases by -115.91% higher compared to the previous year.

For BioToxTech Co, the net margin of 2.5% is down versus 21.7% a few years ago.

The BioToxTech Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
13.30 KRW
Jan 1, 2019
-6.12 KRW
Jan 1, 2020
9.89 KRW
Jan 1, 2021
21.74 KRW
Jan 1, 2022
7.31 KRW
Jan 1, 2023
-14.95 KRW
Jan 1, 2024
-15.55 KRW
Jan 1, 2025
2.47 KRW
The BioToxTech Co Net Margin history
YEARNet MarginYoY
2.47 %-115.91%
-15.55 %+4.01%
-14.95 %-304.55%
7.31 %-66.39%
21.74 %+119.87%
9.89 %-261.64%
-6.12 %-146.00%
13.30 %+144.33%
5.44 %+15.98%
4.69 %-120.05%
-23.42 %-21.97%
-30.01 %-39,445.20%
0.08 %-46.21%
0.14 %+650.42%
0.02 %-92.58%
0.25 %-127.96%
-0.91 %-4,739.37%
0.02 %-29.00%
0.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Net Profit Margin of BioToxTech Co is 2.47 % in 2025.

Net Profit Margin of BioToxTech Co changed from -15.55 % to 2.47 %, representing a -115.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — BioToxTech Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — BioToxTech Co